Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Neutral

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Onconova Therapeutics, Inc. (ONTX)

Pharmaceutical Preparations

https://www.onconova.com

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

375 PHEASANT RUN
NEWTOWN, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/25/2013

Market Cap

20,904,684

Shares Outstanding

21,000,000

Weighted SO

21,003,409

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

JAGX --.--%

IBIO --.--%

GOVX --.--%

OCGN --.--%

TNXP --.--%

SONN --.--%

PALI --.--%

ADIL --.--%

DFFN --.--%

Beta

1.3490

Last Div

0.0000

Range

0.5509-1.45

Chg

-0.0047

Avg Vol

126338

Mkt Cap

20904684

Exch

NASDAQ

Country

US

Phone

267 759 3680

DCF Diff

0.1332

DCF

0.8621

Div Yield

0.0000

P/S

92.4986

EV Multiple

-0.2332

P/FV

3.4821

Div Yield %

0.0000

P/E

-1.1536

PEG

-0.5482

Payout

0.0000

Current Ratio

1.9267

Quick Ratio

1.7415

Cash Ratio

1.7395

DSO

29.0708

DIO

25758.5714

Op Cycle

25787.6422

DPO

114158.0952

CCC

-88370.4530

Gross Margin

0.9071

Op Margin

-85.7212

Pretax Margin

-80.3363

Net Margin

-80.3363

Eff Tax Rate

-0.0199

ROA

-0.9991

ROE

-1.4495

ROCE

-2.2141

NI/EBT

1.0000

EBT/EBIT

0.9372

EBIT/Rev

-85.7212

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

-53.5166

CF/Debt

0.0000

Equity Multi

3.0211

Rec Turnover

12.5556

Pay Turnover

0.0032

Inv Turnover

0.0142

FA Turnover

12.5556

Asset Turnover

0.0124

OCF/Share

-0.8465

FCF/Share

-666.1364

Cash/Share

0.7789

OCF/Sales

-78.8186

FCF/OCF

786.9429

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

-0.0013

Div&CapEx Cov

-0.0013

P/BV

3.4821

P/B

3.4821

P/S

92.4986

P/E

-1.1536

P/FCF

-0.0015

P/OCF

-1.1758

P/CF

-1.1758

PEG

-0.5482

P/S

92.4986

EV Multiple

-0.2332

P/FV

3.4821

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 02, 10:37 Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

Revenue Product Segmentation